For 10 years, the American laboratory Eli Lilly has been working on an experimental treatment (solanezumab) designed to delay the progression of Alzheimer’s disease. The results of a first test, in 2012, were not conclusive.
But one second clinical trial conducted in 2014 with 2,000 patients recruited at an early stage of the disease seemed more positive and had prompted the laboratory to continue its clinical trials with patients with a moderately advanced form of the disease.
No significant impact on cognitive decline
This 3rd clinical trial, the results of which have just been presented by the laboratoryindicate that solanezumab does not “did not meet the primary endpoint of the clinical trial. After 18 months of treatment, patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo”.
The Eli Lilly laboratory will therefore not seek FDA approval for this drug. “The outcome was not what we had hoped for and we understand the disappointment of the millions of people awaiting a potential treatment for Alzheimer’s disease”said Dr. Eric Siemers, medical director at Lilly.
Read also :
Alzheimer’s disease shows signs of slowing down
Alzheimer’s disease: symptoms loved ones should be aware of
